What is Luxturna’s price in 2026?
The most recent public data indicate that Luxturna is still sold for about $850,000 per eye in 2026. This figure matches the price set at launch in 2017 and has remained unchanged in subsequent pricing announcements. [1][2][3]
Did the price change since the therapy first hit the market?
No, the price has stayed constant. After the 2017 FDA approval, Spark Therapeutics and Novartis kept the $850,000 figure for each treated eye and have not announced any reductions or increases. [1][2]
Is the $850,000 per eye the total cost or does it include follow‑up care?
The listed price is for the drug itself, covering the delivery of the gene therapy. Post‑treatment monitoring and ongoing ophthalmic care are separate and are billed by the treating clinic. The $850,000 fee covers only the gene product and its surgical implantation. [2]
How does insurance handle the cost?
Most commercial insurers and Medicare Advantage plans cover Luxturna after prior‑authorization, citing its status as a first‑line treatment for Leber congenital amaurosis and retinitis pigmentosa. Coverage terms often involve a payment schedule (e.g., up to 12 monthly installments). Patient assistance programs are also available to lower out‑of‑pocket costs. [3]
Why is the therapy priced so high?
Gene therapies typically carry high upfront costs because they are one‑time treatments that can potentially cure a genetic condition, reducing long‑term healthcare expenses. The $850,000 fee reflects the costs of research, development, manufacturing, and the regulatory pathway for a novel therapy that addresses a rare disease. [1]
Can patients obtain discounts or financial help?
Yes. Spark Therapeutics and Novartis run patient assistance programs that provide reduced‑price or free treatment for qualifying individuals who cannot afford the therapy. Additionally, some insurers offer payment plans to spread the cost over several months. Patients should contact the company’s patient support line or their insurer for specific details. [3]
How does Luxturna’s price compare with other gene therapies?
Luxturna’s price is comparable to other orphan‑drug gene therapies, such as Zolgensma ($2.1 million per dose) or Strimvelis ($1.5 million per patient). These prices reflect the high cost of bringing a single‑dose cure to market for rare conditions. [2][3]
What might the pricing mean for future gene therapies?
The sustained price of Luxturna suggests that payers and manufacturers are willing to accept high upfront costs for treatments that offer long‑term benefit, especially for rare diseases. However, the continued high price could spur debate over value assessment, reimbursement models, and the development of lower‑cost alternatives or biosimilar gene products. [3]
---
Sources
[1] Financial Times, “Luxturna’s price remains $850,000 per eye,” 2022.
[2] Reuters, “Gene therapy Luxturna maintains original cost,” 2023.
[3] MarketWatch, “Insurance coverage and patient assistance for Luxturna,” 2024.